BARDA Awards $9.27 Million Contract to Evaluate Oral Pill COVID Vaccine
Biotechnology firm Vaxart, Inc. announced on Jan. 19, 2024 that it received a $9.27 million contract from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to fund preparations for a Phase IIb clinical trial to evaluate the company’s oral pill XXB COVID-19 vaccine candidate. The trial is expected to involve 10,000 participants and will […]
U.S. Taxpayers Fund $5 Billion Project NextGen to Develop Novel COVID Vaccines and Drugs
Just three months after the Biden administration announced that U.S. taxpayers would fund a $5 billion initiative called Project NextGen to develop “next generation” COVID-19 vaccines and therapeutics, the U.S. Department of Health and Human Services’ (HHS) awarded $1.4 billion in contracts under the program on Aug. 22, 2023. The total includes “$1 billion for […]
U.S. to Spend Billions on New COVID Vaccines Despite Failure to Prevent Infection
The Biden administration announced earlier this month that the U.S. government will spend at least $5 billion on Project NextGen to rapidly develop “next-generation” SARS-CoV-2 vaccines and treatments despite evidence that current COVID vaccines do not prevent infection and transmission of the new coronavirus.1 Following a similar approach to “Operation Warp Speed” initiated by the […]
